Polyarthritis Nodosa

Researchers are evaluating a new MRI pulse sequence called 3D DL oZTEo to detect bone erosions in the hands of patients with inflammatory arthritis. The study aims to validate this technique against current standard methods like radiography and conventional MRI, as these structural changes are important for diagnosis and treatment decisions in rheumatic conditions. This is an interventional study conducted at Mayo Clinic. Participants will have the FDA-approved oZTEo MRI pulse sequence added to their routine hand MRI scan. The oZTEo images will be anonymized and processed using a deep learning algorithm developed by GE Healthcare. This additional sequence is assessed alongside the standard MRI to compare its ability to detect bone erosions. During the study, researchers will analyze MRI scans with and without the 3D DL oZTEo sequence to determine the presence and number of bone erosions in the hand. Participants must have recent hand radiographs confirming erosions and are scheduled for hand MRI as part of their clinical care. The study measures outcomes on the day of imaging and monitors the accuracy of erosion detection.

Researchers are studying the safety and performance of the LEGION Medial Stabilized insert used in total knee arthroplasty TKA for patients with degenerative joint disease such as osteoarthritis, post-traumatic arthritis, or inflammatory arthritis. This observational study includes both prospective and retro-prospective participants and aims to provide long-term evidence to support product registration worldwide. The study involves three groups receiving different LEGION MS insert combinations with tibia and femoral components Cemented CoCr, Cemented Oxinium, and Cementless options. Participants will be followed for 10 years after their primary knee replacement surgery to monitor outcomes related to the implant. During the study, participants will undergo regular assessments including the Knee Injury and Osteoarthritis Outcome Score for Joint Replacement KOOS JR, Oxford Knee Score, Forgotten Joint Score, and EuroQol Five-Dimensional EQ-5D-5L questionnaires at multiple timepoints from 6 weeks up to 10 years post-surgery. Implant survivorship will be tracked at intervals up to 10 years, with all participants consenting to follow-up visits and outcome reporting to evaluate long-term device safety and effectiveness.

Researchers are studying the experiences of people who develop rheumatic immune-related adverse events irAEs after receiving immune checkpoint inhibitor immunotherapy. This study aims to understand how severe these events are, how they affect daily function, and the attitudes of patients towards different aspects of these side effects. The research focuses on conditions like arthritis and polymyalgia rheumatica that arise following this cancer treatment. This observational study does not involve any drug or treatment interventions. Instead, it gathers information through qualitative assessments from patients diagnosed by rheumatologists with inflammatory arthritis or polymyalgia rheumatica as irAEs after immune checkpoint inhibitor therapy. The study is sponsored by M.D. Anderson Cancer Center and will collect data over about one year. Participants will engage in interviews to share their experiences, which will help researchers evaluate the safety and adverse events associated with these immune-related conditions. The study includes monitoring adverse events throughout the study period. The total involvement duration averages one year, allowing for comprehensive understanding of the impact and progression of these rheumatic irAEs.

Researchers are evaluating the effectiveness of antigravity treadmill training and body weight-supported treadmill training for rehabilitation in elderly patients aged 60 to 75 years who have recently undergone hip or knee replacement surgery. The study compares these two methods to conventional gait training to see which approach may better support recovery and walking ability after surgery. Participants will be randomly assigned to one of three groups antigravity treadmill training, body weight-supported treadmill training, or conventional rehabilitation. Each group will undergo a 6-week program with five sessions per week. The antigravity treadmill uses air pressure to reduce weight on joints with gradually decreasing support, while the body weight-supported treadmill uses a harness to partially offload weight with a steady level of support. The conventional group receives standard postoperative therapy including gait training and physical therapy techniques. During the study, participants will receive comprehensive daily therapy including kinesitherapy, ergotherapy, and individualized physical therapy procedures. Researchers will assess outcomes such as pain and function using the Western Ontario and McMaster Universities Osteoarthritis Index, balance, mental health, stress, and walking parameters both before and after the 6-week intervention. The total participation period includes baseline assessments and the 6-week therapy program under professional supervision.

Researchers are evaluating the Aptis PRUJ prosthesis in patients with disorders of the proximal radial ulna joint, including arthritis, instability, and decreased motion. This prospective, multi-center, single-arm clinical trial aims to assess the safety and effectiveness of this prosthetic implant as a treatment option. The study will enroll 84 patients across nine centers in the US, with a total duration of about 36 months including enrollment and follow-up. Participants will receive the investigational Aptis PRUJ prosthesis, which replaces the proximal radial ulna joint. The study includes a 12-month enrollment period followed by a 24-month follow-up. After surgery, participants will have annual visits until the last patient reaches two years post-operation. This structure allows researchers to monitor the implants performance and patient outcomes over time. During the study, participants will undergo multiple assessments including effectiveness evaluations and radiographic imaging at 6 weeks, 3 months, 6 months, 12 months, and 24 months post-implantation. Health economic outcomes will also be measured at these intervals. The primary outcome is success at 24 months. Safety and follow-up visits will continue annually to monitor long-term results. Participants can expect regular visits and evaluations throughout the study period.

Researchers are studying how daily changes in mood, pain, and activity relate to acute and chronic pain using a smartphone app called SOMA. The study includes people with acute pain, chronic pain, and healthy controls. A smaller sub-study focuses on patients with chronic low back pain, failed back surgery syndrome, or fibromyalgia, using EEG testing to explore brain and behavior patterns that might predict treatment responses. Participants will use the SOMA app daily for four months to track their symptoms and activities. Those in the sub-study will also attend an in-person EEG session to perform specific tasks before starting app use. Data collected will help identify patterns linked to pain transition, recovery, or flare-ups. The study also monitors app engagement and symptom dynamics over up to 12 months. During the study, participants will report pain, mood, and activity daily through the app. Researchers will analyze these reports alongside baseline and follow-up EEG and behavioral tests. Outcomes include measuring the likelihood of acute pain becoming chronic and understanding mood and pain interactions. Participants progress and app usage will be observed over time to assess feasibility and treatment effects.

Camptodactyly-Arthropathy-Coxa Vara-Pericarditis CACP syndrome is a rare inherited disorder caused by mutations in the PRG4 gene. It is characterized by the combination of camptodactyly bent fingers or toes, joint problems without inflammation, and deformity of the hip bone, sometimes also involving heart and lung issues. The syndrome shows variable symptoms and may be underdiagnosed due to its rarity and resemblance to juvenile arthritis. This European multicenter study aims to collect detailed clinical, genetic, and therapeutic data to better understand the diseases characteristics and progression in children diagnosed with CACP syndrome. Participants are children diagnosed with CACP syndrome confirmed by genetic testing who were diagnosed between 2005 and early 2026. The study involves regular clinical visits approximately every six months to monitor symptoms, joint function, and possible complications like pericarditis. Imaging and lab tests are done every 1 to 2 years or as needed. No specific drug treatment is available, and the study focuses on observing the disease course, treatment approaches, and genotype-phenotype relationships over a 10-year period. Throughout the study, researchers will collect epidemiological and clinical information, including disease incidence, geographic and ethnic distribution, symptom progression, and treatment outcomes. Patient disability, pain levels, and well-being will be tracked using questionnaires. The study will also document any misdiagnoses before confirmation of CACP. Monitoring adverse events related to treatments used will be included. This long-term observation will help improve understanding and management of CACP syndrome in affected children.

Researchers are evaluating a new combined fatigue intervention COMFI for people with inflammatory arthritis IA, including rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Fatigue is a common and severe problem in IA patients, affecting their quality of life and ability to work. This study aims to test if combining a cognitive behavioral approach and physical activity can reduce fatigue severity and impact in patients from Denmark and Sweden. The COMFI intervention is a 24-week outpatient program consisting of six group sessions based on cognitive behavioral approaches covering topics such as fatigue, physical activity, energy management, and peer support. A seventh booster group session is held at week 24, along with an optional individual session between weeks 6 and 9, and a support line available from weeks 13 to 23. Participants join groups of 8-10 people, with the intervention tested in four groups across two sites. Participants will complete patient-reported fatigue outcome measures at baseline, 3, 6, and 12 months, using questionnaires and databases. Physical activity and fitness will be measured at baseline and 6 months. Attendance and time use will be recorded by health professionals. The study also includes two focus group interviews for qualitative evaluation. Data confidentiality and ethical standards are maintained throughout the study, which will provide insights into the feasibility and meaningfulness of the intervention for IA patients.

This research aims to examine how three different weekly amounts of physical activity45 minutes, 90 minutes, or 150 minutesaffect symptoms in people with arthritis and related conditions such as rheumatoid arthritis, gout, lupus, and fibromyalgia. The study focuses on understanding the dose-response relationship between exercise levels and arthritis outcomes to help guide effective symptom management. Participants will be randomly assigned to one of the three physical activity goals. Each participant will take part in a 6-month program called the DREAM Adaptive Intervention, which includes monthly coaching calls, the Arthritis Foundations Walk With Ease Guidebook, behavioral lessons, and a Fitbit to track activity. Additional support through calls, texts, or emails may be provided if participants have difficulty meeting their activity goals. During the study, participants will be assessed on physical function using the 6 Minute Walk Test and chair stand tests, as well as measures of physical and mental health-related quality of life, pain intensity, and depression symptoms. These assessments will be conducted at the start, 6 months, and 12 months where applicable. The study follows participants for up to 12 months to monitor changes in these outcomes as related to their physical activity levels.

Researchers are studying how bone turnover markers BTMs change during and after short-term glucocorticoid treatment in patients with inflammatory joint diseases like rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. The study aims to improve understanding of BTM reliability during glucocorticoid use, since these medications suppress BTMs and increase fracture risk. This knowledge could help optimize patient care and reduce side effects and healthcare costs. Participants include those newly diagnosed with inflammatory joint diseases starting disease-modifying antirheumatic drugs DMARDs, some with glucocorticoid bridging and others without, as well as patients on stable DMARD treatment receiving glucocorticoid injections. Patients are grouped by disease type, glucocorticoid use, and agemenopausal status. Bone turnover markers P1NP and CTX1 will be measured every 4 weeks up to 6 months after the last glucocorticoid dose. During the study, researchers will track bone marker levels to assess their changes over time after stopping glucocorticoids or during inflammation treatment without glucocorticoids. The main measurement is P1NP level 3 months after stopping glucocorticoids, with additional measures up to 6 months. This observational study will follow patients for several months to better understand BTM dynamics and improve osteoporosis management in this population.